Is 500680 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 500680?
Other financial metrics that can be useful for relative valuation.
|What is 500680's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 500680's PE Ratio compare to its peers?
|500680 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
524494 Ipca Laboratories
500660 GlaxoSmithKline Pharmaceuticals
AJANTPHARM Ajanta Pharma
506943 J. B. Chemicals & Pharmaceuticals
Price-To-Earnings vs Peers: 500680 is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the peer average (39.8x).
Price to Earnings Ratio vs Industry
How does 500680's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 500680 is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the Indian Pharmaceuticals industry average (24.1x)
Price to Earnings Ratio vs Fair Ratio
What is 500680's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||45.2x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 500680's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 500680 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 500680 (₹4401.45) is trading above our estimate of fair value (₹3168.59)
Significantly Below Fair Value: 500680 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.